Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um estudo para testar a eficácia e a segurança do staccato alprazolam em participantes do estudo com 12 anos de idade ou mais com convulsões prolongadas estereotipadas

5 de novembro de 2026 atualizado por: UCB Biopharma SRL

Um estudo duplo-cego, randomizado, controlado por placebo, multicêntrico, ambulatorial, de grupos paralelos para avaliar a eficácia e a segurança do staccato alprazolam em participantes do estudo com 12 anos de idade ou mais com convulsões prolongadas estereotipadas

The purpose of the study is to assess the success of a single administration of Staccato alprazolam compared with placebo both in rapidly terminating a seizure episode within 90 seconds and with no recurrence of seizure(s) up to 2 hours after investigational medicinal product (IMP) administration.

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Estimado)

350

Estágio

  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

  • Nome: UCB Cares
  • Número de telefone: 1-844-599-2273 (USA)
  • E-mail: UCBCares@ucb.com

Locais de estudo

      • Aachen, Alemanha
        • Retirado
        • Ep0162 40577
      • Berlin, Alemanha
        • Recrutamento
        • Ep0162 40683
      • Bielefeld, Alemanha
        • Recrutamento
        • Ep0162 40685
      • Erlangen, Alemanha
        • Recrutamento
        • Ep0162 40023
      • Frankfurt am Main, Alemanha
        • Recrutamento
        • Ep0162 40645
      • Kehl-kork, Alemanha
        • Concluído
        • Ep0162 40689
      • Marburg, Alemanha
        • Recrutamento
        • Ep0162 40529
      • München, Alemanha
        • Retirado
        • Ep0162 40724
      • Fitzroy, Austrália
        • Recrutamento
        • Ep0162 30016
      • Herston, Austrália
        • Recrutamento
        • Ep0162 30030
      • Melbourne, Austrália
        • Retirado
        • Ep0162 30027
      • South Brisbane, Austrália
        • Ativo, não recrutando
        • Ep0162 30031
      • Blagoevgrad, Bulgária
        • Recrutamento
        • Ep0162 40650
      • Pazardzhik, Bulgária
        • Recrutamento
        • Ep0162 40708
      • Pleven, Bulgária
        • Concluído
        • Ep0162 40665
      • Pleven, Bulgária
        • Concluído
        • Ep0162 40709
      • Sofia, Bulgária
        • Concluído
        • Ep0162 40651
      • Beijing, China
        • Recrutamento
        • Ep0162 20246
      • Beijing, China
        • Recrutamento
        • Ep0162 20299
      • Beijing, China
        • Retirado
        • Ep0162 20128
      • Beijing, China
        • Concluído
        • Ep0162 20268
      • Changchun, China
        • Recrutamento
        • Ep0162 20261
      • Chengdu, China
        • Recrutamento
        • Ep0162 20133
      • Chengdu, China
        • Recrutamento
        • Ep0162 20137
      • Chongqing, China
        • Retirado
        • Ep0162 20250
      • Chongqing, China
        • Recrutamento
        • Ep0162 20334
      • Fuzhou, China
        • Recrutamento
        • Ep0162 20179
      • Guangzhou, China
        • Recrutamento
        • Ep0162 20269
      • Guangzhou, China
        • Recrutamento
        • Ep0162 20300
      • Guangzhou, China
        • Recrutamento
        • Ep0162 20124
      • Guangzhou, China
        • Concluído
        • Ep0162 20260
      • Guangzhou, China
        • Concluído
        • Ep0162 20264
      • Hangzhou, China
        • Recrutamento
        • Ep0162 20022
      • Kunming, China
        • Recrutamento
        • Ep0162 20320
      • Lanzhou, China
        • Recrutamento
        • Ep0162 20258
      • Nanchang, China
        • Retirado
        • Ep0162 20253
      • Nanjing, China
        • Recrutamento
        • Ep0162 20267
      • Nanning, China
        • Recrutamento
        • Ep0162 20331
      • Qingdao, China
        • Recrutamento
        • Ep0162 20333
      • Shanghai, China
        • Retirado
        • Ep0162 20123
      • Shanghai, China
        • Recrutamento
        • Ep0162 20292
      • Shenzhen, China
        • Retirado
        • Ep0162 20332
      • Shijiazhuang, China
        • Recrutamento
        • Ep0162 20289
      • Suzhou, China
        • Recrutamento
        • Ep0162 20119
      • Tianjin, China
        • Recrutamento
        • Ep0162 20257
      • Wenzhou, China
        • Recrutamento
        • Ep0162 20025
      • Wuhan, China
        • Retirado
        • Ep0162 20252
      • Yinchuan, China
        • Retirado
        • Ep0162 20255
      • Zhanjiang, China
        • Recrutamento
        • Ep0162 20262
      • Zhengzhou, China
        • Recrutamento
        • Ep0162 20251
      • Barcelona, Espanha
        • Recrutamento
        • Ep0162 40160
      • L'Hospitalet de Llobregat, Espanha
        • Recrutamento
        • Ep0162 40157
      • Madrid, Espanha
        • Recrutamento
        • Ep0162 40540
      • Pamplona, Espanha
        • Recrutamento
        • Ep0162 40352
      • Seville, Espanha
        • Recrutamento
        • Ep0162 40668
      • Terrassa, Espanha
        • Recrutamento
        • Ep0162 40453
      • Valencia, Espanha
        • Recrutamento
        • Ep0162 40230
      • Valladolid, Espanha
        • Concluído
        • Ep0162 40667
    • Arizona
      • Phoenix, Arizona, Estados Unidos, 85004
        • Recrutamento
        • Ep0162 50506
      • Scottsdale, Arizona, Estados Unidos, 85253
        • Recrutamento
        • Ep0162 50720
    • Arkansas
      • Little Rock, Arkansas, Estados Unidos, 72205
        • Concluído
        • Ep0162 50494
    • California
      • Downey, California, Estados Unidos, 90242
        • Recrutamento
        • Ep0162 50118
      • La Jolla, California, Estados Unidos, 92037
        • Recrutamento
        • Ep0162 50416
      • Long Beach, California, Estados Unidos, 90806
        • Recrutamento
        • Ep0162 50702
      • Los Angeles, California, Estados Unidos, 90095
        • Retirado
        • Ep0162 50505
      • Orange, California, Estados Unidos, 92868
        • Concluído
        • Ep0162 50492
      • Poway, California, Estados Unidos, 92064
        • Retirado
        • Ep0162 50722
      • Sacramento, California, Estados Unidos, 95817
        • Recrutamento
        • Ep0162 50716
    • Connecticut
      • New Haven, Connecticut, Estados Unidos, 06519
        • Concluído
        • Ep0162 50367
    • District of Columbia
      • Washington D.C., District of Columbia, Estados Unidos, 20037
        • Recrutamento
        • Ep0162 50088
    • Florida
      • Boca Raton, Florida, Estados Unidos, 33486
        • Retirado
        • Ep0162 50721
      • Gulf Breeze, Florida, Estados Unidos, 32561
        • Concluído
        • Ep0162 50515
      • Jacksonville, Florida, Estados Unidos, 32224-1865
        • Recrutamento
        • Ep0162 50342
      • Jacksonville, Florida, Estados Unidos, 32209-6533
        • Recrutamento
        • Ep0162 50508
      • Miami, Florida, Estados Unidos, 33136
        • Recrutamento
        • Ep0162 50199
      • Miami, Florida, Estados Unidos, 33176
        • Recrutamento
        • Ep0162 50676
      • Orlando, Florida, Estados Unidos, 32806
        • Concluído
        • Ep0162 50509
      • Rockledge, Florida, Estados Unidos, 32955
        • Recrutamento
        • Ep0162 50703
      • Tampa, Florida, Estados Unidos, 33606
        • Recrutamento
        • Ep0162 50308
    • Hawaii
      • Honolulu, Hawaii, Estados Unidos, 96817
        • Recrutamento
        • Ep0162 50323
    • Idaho
      • Boise, Idaho, Estados Unidos, 83702
        • Recrutamento
        • Ep0162 50512
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60611
        • Recrutamento
        • Ep0162 50493
      • Springfield, Illinois, Estados Unidos, 62702
        • Retirado
        • Ep0162 50375
    • Indiana
      • Fort Wayne, Indiana, Estados Unidos, 46804
        • Recrutamento
        • Ep0162 50504
    • Kentucky
      • Lexington, Kentucky, Estados Unidos, 40536
        • Retirado
        • Ep0162 50561
    • Louisiana
      • New Orleans, Louisiana, Estados Unidos, 70122
        • Recrutamento
        • Ep0162 50517
      • New Orleans, Louisiana, Estados Unidos, 70121
        • Retirado
        • Ep0162 50395
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21287
        • Retirado
        • Ep0162 50093
      • Bethesda, Maryland, Estados Unidos, 20817
        • Retirado
        • Ep0162 50488
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02118
        • Recrutamento
        • Ep0162 50615
      • Boston, Massachusetts, Estados Unidos, 02215
        • Concluído
        • Ep0162 50047
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48109
        • Concluído
        • Ep0162 50110
    • Missouri
      • St Louis, Missouri, Estados Unidos, 63110
        • Recrutamento
        • Ep0162 50507
    • Nevada
      • Las Vegas, Nevada, Estados Unidos, 89128
        • Retirado
        • Ep0162 50499
    • New Jersey
      • Neptune City, New Jersey, Estados Unidos, 07753
        • Retirado
        • Ep0162 50626
      • New Brunswick, New Jersey, Estados Unidos, 08901
        • Recrutamento
        • Ep0162 50299
    • New York
      • Buffalo, New York, Estados Unidos, 14221
        • Recrutamento
        • Ep0162 50497
      • New Hyde Park, New York, Estados Unidos, 11042
        • Concluído
        • Ep0162 50625
      • New York, New York, Estados Unidos, 10016
        • Recrutamento
        • Ep0162 50298
      • New York, New York, Estados Unidos, 10029
        • Recrutamento
        • Ep0162 50490
      • New York, New York, Estados Unidos, 10075
        • Recrutamento
        • Ep0162 50518
      • Rochester, New York, Estados Unidos, 14642
        • Recrutamento
        • Ep0162 50034
    • North Carolina
      • Charlotte, North Carolina, Estados Unidos, 28204
        • Recrutamento
        • Ep0162 50514
      • Charlotte, North Carolina, Estados Unidos, 28207
        • Retirado
        • Ep0162 50487
      • Durham, North Carolina, Estados Unidos, 27705
        • Recrutamento
        • Ep0162 50715
    • Ohio
      • Akron, Ohio, Estados Unidos, 44308
        • Retirado
        • Ep0162 50371
      • Cleveland, Ohio, Estados Unidos, 44195
        • Retirado
        • Ep0162 50528
    • Oregon
      • Portland, Oregon, Estados Unidos, 97239-3098
        • Retirado
        • Ep0162 50510
      • Portland, Oregon, Estados Unidos, 97227
        • Concluído
        • Ep0162 50724
      • Portland, Oregon, Estados Unidos, 97239
        • Recrutamento
        • Ep0162 50701
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19104
        • Recrutamento
        • Ep0162 50096
      • Philadelphia, Pennsylvania, Estados Unidos, 19107
        • Recrutamento
        • Ep0162 50364
      • Philadelphia, Pennsylvania, Estados Unidos, 19140
        • Recrutamento
        • Ep0162 50089
      • Pittsburgh, Pennsylvania, Estados Unidos, 15212
        • Recrutamento
        • Ep0162 50511
      • Pittsburgh, Pennsylvania, Estados Unidos, 15213
        • Recrutamento
        • Ep0162 50491
    • Tennessee
      • Chattanooga, Tennessee, Estados Unidos, 37403
        • Recrutamento
        • Ep0162 50700
      • Memphis, Tennessee, Estados Unidos, 38103-2800
        • Recrutamento
        • Ep0162 50513
      • Nashville, Tennessee, Estados Unidos, 37232
        • Recrutamento
        • Ep0162 50103
    • Texas
      • Austin, Texas, Estados Unidos, 78749
        • Recrutamento
        • Ep0162 50731
      • Houston, Texas, Estados Unidos, 77459
        • Recrutamento
        • Ep0162 50525
      • Houston, Texas, Estados Unidos, 77030
        • Recrutamento
        • Ep0162 50714
      • Round Rock, Texas, Estados Unidos, 78681
        • Retirado
        • Ep0162 50496
    • Utah
      • Salt Lake City, Utah, Estados Unidos, 84132
        • Recrutamento
        • Ep0162 50473
    • Virginia
      • Winchester, Virginia, Estados Unidos, 22601
        • Recrutamento
        • Ep0162 50726
      • Bron, França
        • Recrutamento
        • Ep0162 40681
      • Bron, França
        • Retirado
        • Ep0162 40688
      • Dijon, França
        • Retirado
        • Ep0162 40680
      • Marseille, França
        • Retirado
        • Ep0162 40130
      • Paris, França
        • Recrutamento
        • Ep0162 40682
      • Paris, França
        • Retirado
        • Ep0162 40019
      • Rennes, França
        • Recrutamento
        • Ep0162 40201
      • Strasbourg, França
        • Recrutamento
        • Ep0162 40199
      • Balassagyarmat, Hungria
        • Recrutamento
        • Ep0162 40666
      • Budapest, Hungria
        • Recrutamento
        • Ep0162 40673
      • Budapest, Hungria
        • Recrutamento
        • Ep0162 40704
      • Debrecen, Hungria
        • Recrutamento
        • Ep0162 40653
      • Catanzaro, Itália
        • Retirado
        • Ep0162 40690
      • Genova, Itália
        • Recrutamento
        • Ep0162 40674
      • Milan, Itália
        • Recrutamento
        • Ep0162 40144
      • Pavia, Itália
        • Recrutamento
        • Ep0162 40477
      • Roma, Itália
        • Recrutamento
        • Ep0162 40257
      • Roma, Itália
        • Concluído
        • Ep0162 40675
      • Fukuoka, Japão
        • Recrutamento
        • Ep0162 20248
      • Hachioji-shi, Japão
        • Recrutamento
        • Ep0162 20070
      • Hamamatsu, Japão
        • Retirado
        • Ep0162 20237
      • Hiroshima, Japão
        • Recrutamento
        • Ep0162 20249
      • Hōfu, Japão
        • Recrutamento
        • Ep0162 20236
      • Itami, Japão
        • Recrutamento
        • Ep0162 20239
      • Kodaira, Japão
        • Recrutamento
        • Ep0162 20143
      • Koshi-shi, Japão
        • Recrutamento
        • Ep0162 20315
      • Kyoto, Japão
        • Recrutamento
        • Ep0162 20147
      • Nagakute, Japão
        • Concluído
        • Ep0162 20243
      • Nagoya, Japão
        • Recrutamento
        • Ep0162 20235
      • Niigata, Japão
        • Recrutamento
        • Ep0162 20238
      • Osaka, Japão
        • Recrutamento
        • Ep0162 20302
      • Sapporo, Japão
        • Recrutamento
        • Ep0162 20316
      • Shimotsuga-gun, Japão
        • Recrutamento
        • Ep0162 20337
      • Shinjuku-ku, Japão
        • Recrutamento
        • Ep0162 20297
      • Shizuoka, Japão
        • Recrutamento
        • Ep0162 20240
      • Suita, Japão
        • Recrutamento
        • Ep0162 20242
      • Tōon, Japão
        • Recrutamento
        • Ep0162 20266
      • Yamagata, Japão
        • Recrutamento
        • Ep0162 20244
      • Ōmura, Japão
        • Recrutamento
        • Ep0162 20241
      • Bydgoszcz, Polônia
        • Recrutamento
        • Ep0162 40707
      • Gdansk, Polônia
        • Recrutamento
        • Ep0162 40677
      • Krakow, Polônia
        • Retirado
        • Ep0162 40219
      • Krakow, Polônia
        • Recrutamento
        • Ep0162 40842
      • Krakow, Polônia
        • Concluído
        • Ep0162 40502
      • Lublin, Polônia
        • Concluído
        • Ep0162 40676
      • Nowa Sól, Polônia
        • Recrutamento
        • Ep0162 40091
      • Poznan, Polônia
        • Retirado
        • Ep0162 40153
      • Świdnik, Polônia
        • Concluído
        • Ep0162 40678
      • Birmingham, Reino Unido
        • Recrutamento
        • Ep0162 40686
      • Cardiff, Reino Unido
        • Retirado
        • Ep0162 40300
      • Glasgow, Reino Unido
        • Recrutamento
        • Ep0162 40735
      • London, Reino Unido
        • Recrutamento
        • Ep0162 40833
      • Oxford, Reino Unido
        • Recrutamento
        • Ep0162 40163
      • Salford, Reino Unido
        • Recrutamento
        • Ep0162 40108
      • Brno, Tcheca
        • Recrutamento
        • Ep0162 40670
      • Ostrava - Poruba, Tcheca
        • Recrutamento
        • Ep0162 40672
      • Prague, Tcheca
        • Recrutamento
        • Ep0162 40671
      • Prague, Tcheca
        • Recrutamento
        • Ep0162 40714
      • Prague, Tcheca
        • Concluído
        • Ep0162 40063

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

12 anos e mais velhos (Filho, Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Participant must be ≥12 years of age at the Baseline/Randomization Visit

  • Participant must have a study caregiver ≥18 years of age at the Screening Visit; the study caregiver(s) must be a relative, partner, friend, or legally authorized representative (LAR) of the participant, or a person who provides daily care to the participant and has a significant personal relationship with the participant; the study caregiver(s) must be able to recognize and observe the participant's seizures

  • Participants with an established diagnosis of focal or generalized epilepsy or combined focal and generalized epilepsy with a documented history of stereotypical episodes of prolonged seizures that includes at least 1 of the following:

    1. Generalized seizure episodes starting with a flurry of absence seizures or myoclonic seizures with a minimum total duration of 5 minutes
    2. Episodes of a focal seizure with a minimum duration of 3 minutes
    3. Episodes of a focal seizure or a flurry of myoclonic seizures for at least 90 seconds followed by a generalized/bilateral tonic-clonic seizure with a minimum total duration of 3 minutes
  • Prior to the Screening Visit, participant has experienced ≥4 stereotypical episodes of prolonged seizures in the past 6 months, and the last 2 stereotypical episodes of prolonged seizures must have occurred within the 3 months prior to the Screening Visit

  • Participant has had a documented brain computerized tomography or magnetic resonance imaging review, performed after diagnosis of epilepsy and within the 5 years prior to the Screening Visit, that confirms the absence of a progressive neurological disorder

  • Participant is receiving a regimen of antiseizure medications (ASMs) that has been stable (ie, no addition or removal of ASM[s]; dose adjustments are permitted to ASM[s]; dose adjustments are not permitted for benzodiazepines) for 30 days prior to the Screening Visit

  • Male and female participants:

    1. A male participant must agree to use contraception during the Outpatient Treatment Period and for at least 7 days after IMP administration and refrain from donating sperm during this period
    2. A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies:

    i) Not a woman of childbearing potential (WOCBP) OR ii) A WOCBP who agrees to follow the contraceptive guidance during the Outpatient Treatment Period and for at least 30 days after IMP administration

  • Participant is capable of giving signed informed consent (or giving assent, where required), which includes compliance with the requirements and restrictions listed in the informed consent form (ICF), the protocol, and the individualized participant management plan (iPMP). The ICF or a specific assent form, where required, will be signed and dated by minors

  • The participant's study caregiver(s) must be capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF, the protocol, and the iPMP

Exclusion Criteria:

  • Participant has a current history of alcohol or drug use disorder, as defined in the Diagnostic and Statistical Manual of Mental Disorders 5, within the previous 1 year
  • Participant has a known hypersensitivity to any components of the IMP or comparable drugs (and/or an investigational device) as stated in this protocol or to albuterol (or similar bronchospasm rescue medication if needed to meet country-specific requirements)
  • Participant has a diagnosis of atrial fibrillation or mitral stenosis
  • Participant has a history of convulsive (generalized tonic-clonic) status epilepticus in the 8 weeks prior to the Screening Visit
  • Participant has a history or presence of known nonepileptic seizures which cannot be distinguished from qualifying epileptic seizures
  • Participant has a clinically significant known airway hypersensitivity (eg, bronchospasm to known allergens, such as pollen, animals, or food) and/or acute respiratory signs/symptoms (eg, shortness of breath, wheezing on lung auscultation)
  • Participant has a clinically significant chronic pulmonary disorder other than mild asthma (eg, chronic obstructive pulmonary disease, restrictive lung diseases [including idiopathic pulmonary fibrosis]) and/or recent history or presence of hemoptysis or pneumothorax
  • Participant has had a positive antigen test for acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and experienced moderate to severe signs/symptoms of respiratory distress necessitating hospitalization or outpatient treatment such as ambulatory oxygen, extensive treatment with inhaler medications, and/or oral medications for a duration of 4 weeks or more, unless full resolution occurred at least 6 months prior to Screening
  • Participant has experienced a upper respiratory tract infection within 4 weeks or bronchitis/pneumonia within 3 months before the Screening Visit
  • Participant has a history or presence of acute narrow-angle glaucoma
  • Participant has a condition for which oral alprazolam is contraindicated (eg, myasthenia gravis, severe respiratory insufficiency, and sleep apnea syndrome)
  • Participant has a history or presence of long QT syndrome, a family history of sudden death due to long QT syndrome, or unexplained syncope
  • Chronic use of benzodiazepines for more than 3 days within a period of 7 days will be allowed for approximately 30 % of study participants
  • Participant is taking any drug that is a strong CYP3A4 inhibitor, including azole antifungal agents (ketoconazole and itraconazole) and nefazodone
  • Participant is taking any opioids (eg, fentanyl, oxycodone, morphine) or sedative hypnotics on a chronic basis
  • Participant is taking nonselective beta blockers on a chronic basis
  • Participant is taking pharmacotherapy for an active major psychiatric disorder where major changes in regimen are needed or anticipated during the study
  • Participant has been treated with vagal nerve stimulation (VNS) for less than 6 months or VNS settings have changed within 30 days before the Screening Visit
  • Participant has a clinically significant laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results, according to the judgment of the Investigator
  • Participant has an oxygen saturation <95 % (or less than normal in regions of altitude >2500 meters) for greater than 30 seconds during the Screening Visit. In case of an out-of-range result, 1 repeat will be allowed. If the readings are out of range again, the study participant will be excluded
  • Participant has >2.0x upper limit of normal (ULN) of any of the following: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or >1.0xULN total bilirubin (≥1.5xULN total bilirubin if known Gilbert's syndrome or >2.0xULN total bilirubin for liver impairment)
  • Participant has current unstable liver or biliary disease per Investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis
  • Participant has a QT interval corrected for heart rate (QTc) >450 msec (males), QTc interval >470 msec (females), or QTc interval >480 msec (participants with bundle branch block), PR interval ≥220 msec, or any other clinically significant electrocardiogram (ECG) abnormality according to the Investigator i) The QTc is the QT interval corrected for heart rate according to Fridericia's formula (QTcF). It is either machine-read or manually over-read
  • Participant has a positive urine screen for drugs of abuse at the Screening Visit
  • Participant has a blood pressure (BP) or heart rate (HR) outside the following range after 5 minutes rest: systolic BP: 90 mmHg to 150 mmHg; diastolic BP: 4 0mmHg to 95 mmHg; HR: 50 bpm to 100 bpm. In case of an out-of-range result, 1 repeat will be allowed. If the readings are out of range again, the study participant will be excluded

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Quadruplicar

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Staccato alprazolam Arm

Participants randomized to this arm will receive a single dose of Staccato alprazolam by inhalation.

Route of administration: Inhalation

Participants will receive one dose of Staccato alprazolam during the Treatment Period.

Outros nomes:
  • UCB7538
Comparador de Placebo: Placebo Arm

Participants randomized to this arm will receive a single dose of placebo by inhalation.

Route of administration: Inhalation

Participants will receive one dose of placebo during the Treatment Period.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Treatment success for the treated seizure within 90 seconds after investigational medicinal product (IMP) administration
Prazo: From start of IMP treatment through 6 hours

Treatment success for the treated seizure is defined as termination of the seizure within 90 seconds after IMP administration.

From start of IMP treatment through 6 hours
Treatment success for the treated seizure with no recurrence up to 2 hours
Prazo: From start of IMP treatment through 2 hours

Treatment success for the treated seizure is defined as termination of the treated seizure within 90 seconds after IMP administration and no recurrence of seizure(s) from IMP administration to 2 hours after IMP administration and no initiation of seizure rescue treatment from 90 seconds to 2 hours after IMP administration.

From start of IMP treatment through 2 hours

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Treatment success for treated seizure with no recurrence after 4 hours
Prazo: From start of IMP treatment through 4 hours

Treatment success defined as termination of the treated seizure within 90 seconds after IMP administration, with no recurrence of seizure(s) up to 4 hours after IMP administration and no initiation of seizure rescue treatment from 90 seconds to 4 hours after IMP administration.

From start of IMP treatment through 4 hours
Treatment success for treated seizure with no recurrence after 6 hours
Prazo: From start of IMP treatment through 6 hours

Treatment success defined as termination of the treated seizure within 90 seconds after IMP administration, with no recurrence of seizure(s) up to 6 hours after IMP administration and no initiation of seizure rescue treatment from 90 seconds to 6 hours after IMP administration.

From start of IMP treatment through 6 hours
Time from IMP administration to cessation of the treated seizure
Prazo: From start of IMP treatment through 6 hours

The time will be assessed from IMP administration to cessation of the treated seizure (taking administration of seizure rescue treatment as censoring point).

From start of IMP treatment through 6 hours
Frequency of respiratory treatment emergent adverse events (TEAEs)
Prazo: From start of IMP treatment up to the Safety Follow-up Visit (Week 19)

An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP.

From start of IMP treatment up to the Safety Follow-up Visit (Week 19)
Number of subsequent seizure(s) up to 2 hours after IMP administration
Prazo: From start of IMP treatment through 2 hours

The number of subsequent seizure(s) will be assessed up to 2 hours after IMP administration.

From start of IMP treatment through 2 hours
Time to first subsequent seizure up to 2 hours after IMP administration
Prazo: From start of IMP treatment through 2 hours

The time to first subsequent seizure will be assessed up to 2 hours after IMP administration and is defined as time from end of IMP treated seizure to start of first subsequent seizure.

From start of IMP treatment through 2 hours

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Diretor de estudo: UCB Cares, 001 844 599 2273 (UCB)

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

7 de dezembro de 2021

Conclusão Primária (Estimado)

29 de março de 2027

Conclusão do estudo (Estimado)

29 de março de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

30 de setembro de 2021

Enviado pela primeira vez que atendeu aos critérios de CQ

30 de setembro de 2021

Primeira postagem (Real)

14 de outubro de 2021

Atualizações de registro de estudo

Última Atualização Postada (Real)

6 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

5 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • EP0162
  • 2021-002686-18 (Número EudraCT)
  • U1111-1303-2588 (Outro identificador: Universal Trial Number (UTN))
  • 2024-510950-29 (Identificador de registro: EU CT Number)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of reidentifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Prazo de Compartilhamento de IPD

Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Critérios de acesso de compartilhamento IPD

Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • SEIVA
  • CSR

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

produto fabricado e exportado dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .